HTA Quarterly | Spring 2019
By Xcenda |
In this issue, we explore the proposed rule from the Centers for Medicare & Medicaid Services on managed care value-based formulary decisions and consider how patient input can help influence drug development.
Heard on the Street
HTA by the Numbers
£1 Billion
NHS England has entered into a £1 billion agreement with Gilead Sciences, Merck & Co., and AbbVie to purchase hepatitis C drugs at competitive prices in an effort to eradicate hepatitis C over the next 3 years.
Topics:
Market Access
Commercialization